Cite
MLA Citation
Carl Samuelsen et al.. “Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.” Journal of medical economics, vol. 23, 2020, pp. 48–53. http://access.bl.uk/ark:/81055/vdc_100099958646.0x00003b